Welcome to our dedicated page for Harvard Apparatus Regenerative Technology news (Ticker: HRGN), a resource for investors and traders seeking the latest updates and insights on Harvard Apparatus Regenerative Technology stock.
Harvard Apparatus Regenerative Technology, Inc. reports developments as a clinical-stage biotechnology company focused on technology intended to regenerate organs inside the body. Company updates center on its cell-based scaffold platform and the Cellspan Esophageal Implant program for severe esophageal disease, including esophageal atresia and repair of esophageal damage caused by cancer or injury.
Recurring news also covers research collaborations applying the platform to colon repair after colectomy and uterine tissue repair, orphan-drug designations in the U.S. and Europe, patent portfolio updates, clinical-program activity, private placements, convertible debt, financial results, and board composition.
Harvard Apparatus Regenerative Technology (HRGN) has announced a strategic partnership with the Capital Institute of Pediatrics in Beijing, China, focusing on developing treatments for Esophageal Atresia (EA) using their Cellspan Esophageal Implant (CEI) product candidate. The collaboration aims to conduct Investigator Initiated Trials (IITs) to evaluate CEI's safety and efficacy in treating EA. The partnership combines HRGN's regenerative medicine technology with the institute's pediatric expertise to accelerate regulatory approval and improve patient outcomes.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has appointed Mao Zhang as an independent director to its Board of Directors. Zhang, the Founder and CEO of StellarS Capital, brings over 15 years of experience in financial markets, including hedge fund and private equity expertise. This appointment aims to strengthen the company's business innovation, strategy, and finance areas.
Jerry He, chairman of Harvard Apparatus Regenerative Technology, expressed confidence that Zhang's deep business and investment experience will be instrumental in pursuing the company's mission to address unmet patient needs. Zhang, in turn, stated his enthusiasm for joining the board at this important stage of clinical development, highlighting the company's potential to develop novel cell therapies that could change and extend patients' lives through regenerated organs.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has secured a $5 million financing through a private placement of shares to a new investor. The funds will accelerate the clinical development of HRGN's lead product, the HRGN Esophageal Implant (BEI). The FDA has approved a ten-patient phase one and phase two clinical trial to study esophageal repair in adults affected by cancer or injury. There's potential to expand the trial to include pediatric subjects with esophageal birth defects. The private placement involves the sale of 1,388,888 shares at $3.60 per share. CEO Jerry He expressed enthusiasm about the new strategic investor and the opportunity to advance HRGN's clinical trials and pipeline development.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has reported its first quarter 2024 financial results and recent business highlights. The company, which is developing organ regeneration technology, entered into a $1.5 million PIPE financing agreement that closed on April 15, 2024. Additionally, it received $0.5 million in convertible debt from its CEO in February 2024.
For Q1 2024, HRGN reported a net loss of $2.0 million, or $0.15 per share, an improvement from the $3.0 million loss, or $0.24 per share, in Q1 2023. This was mainly due to a $1.5 million share-based compensation expense incurred in Q1 2023, which was not repeated in 2024. However, increased preclinical and clinical trial activities in Q1 2024 offset some of the gains.
As of March 31, 2024, the company had $0.3 million in operating cash. It used $1.0 million in operational cash during the quarter and raised $0.3 million through financing activities. The company also reported a $0.5 million debt financing from a related party.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.